Several studies have indicated that IL-3 and its receptor play important roles in the progression of AML [3,17], and indeed, experiments with a monoclonal antibody that blocks the binding of IL-3 to IL3RA have shown increased survival in AML mouse models [18]. Here, IL3RA is linked to acute myeloid leukemia.